Novartis licenses enzyme tech to boost subcutaneous injections; Cellares trims staff again
Novartis has entered a licensing agreement with South Korea's Alteogen for its hyaluronidase enzyme ALT-B4, which is designed to facilitate subcutaneous delivery of biologic drugs. The deal underscores Novartis' push to improve patient convenience by enabling larger-volume injections under the skin. Separately, cell therapy manufacturer Cellares has announced another round of workforce reductions, though details were not provided.
The licensing agreement signals a strategic shift in how large-volume biologic therapies are administered. By incorporating hyaluronidase technology, Novartis aims to break through traditional volume limits for subcutaneous delivery, potentially reducing the need for intravenous infusions that require clinical settings. This approach aligns with broader industry efforts to shift chronic disease management toward home-based care.
Separately, Cellares' second round of layoffs within a short period highlights ongoing volatility in the cell therapy manufacturing sector. While the company has not disclosed specifics, repeated workforce reductions often indicate recalibration amid capital constraints or shifting production priorities. The two developments together illustrate contrasting fortunes in drug development—innovation partnerships advancing while manufacturing startups consolidate.
Patients with chronic conditions requiring biologic treatments could benefit most if subcutaneous delivery becomes viable, potentially reducing hospital visits and improving quality of life. Healthcare systems may see lower infusion-related costs, though pricing remains uncertain. The Cellares reductions could signal instability in the cell therapy supply chain, which may affect research timelines or treatment availability. Investors and biotech employees are directly exposed to these shifts, while patients ultimately depend on whether such efficiency gains translate into accessible, affordable therapies.